OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
OPKO Biologics, a subsidiary of OPKO Health, dosed the first participant in a first-in-human Phase 1/2a trial of OPK-8801001, a long-acting growth hormone receptor antagonist for acromegaly. The drug is designed for once-weekly administration using stabilizer-based technology, and preclinical data showed approximately 20-fold greater receptor antagonism in vitro than pegvisomant.
Key figures
- Drug Name
- OPK-8801001
- Phase Of Trial
- Phase 1/2a
- Preclinical note
- approximately 20-fold greater growth hormone receptor antagonism in vitro compared with pegvisomant
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.